4.7 Article

A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells

Journal

CHEMICAL COMMUNICATIONS
Volume 49, Issue 67, Pages 7442-7444

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c3cc44508a

Keywords

-

Funding

  1. Health Labour Sciences Research Grant (Research on Publicly Essential Drugs and Medical Devices) from the Ministry of Health, Labour and Welfare of Japan
  2. Ministry of Education, Culture, Sports, Science and Technology in Japan (MEXT) [21300190, 23650288]
  3. MEXT [23800045]
  4. Grants-in-Aid for Scientific Research [23650288, 23800045, 25870392, 21300190] Funding Source: KAKEN

Ask authors/readers for more resources

Herein, we report the preparation of genetically engineered protein cages (HspG41C-SP94), taken up selectively by human hepatocellular carcinoma (HCC) cells. An engineered protein cage-doxorubicin (DOX) conjugate was as cytotoxic as free DOX against HCC cells but much less cytotoxic against normal hepatocytes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available